Latest & greatest articles for losartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on losartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on losartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for losartan

1. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome

Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome 30261963 2018 09 28 1558-3597 72 14 2018 Oct 02 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. 1613-1618 S0735-1097(18)35818-2 10.1016/j.jacc.2018.07.052 Beta-blockers are the standard treatment in Marfan syndrome (MFS). Recent clinical trials with limited follow-up yielded conflicting (...) results on losartan's effectiveness in MFS. The present study aimed to evaluate the benefit of losartan compared with atenolol for the prevention of aortic dilation and complications in Marfan patients over a longer observation period (>5 years). A total of 128 patients included in the previous LOAT (LOsartan vs ATenolol) clinical trial (64 in the atenolol and 64 in the losartan group) were followed up for an open-label extension of the study, with the initial treatment maintained. Mean clinical

EvidenceUpdates2018

2. Losartan

Losartan Top results for losartan - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for losartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy

Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy 29222139 2018 04 03 1524-4539 137 14 2018 Apr 03 Circulation Circulation Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot (...) of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot. The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired tetralogy of Fallot and RV dysfunction (RV ejection fraction [EF] <50%) but without severe valvular dysfunction were

EvidenceUpdates2018

4. Atenolol versus losartan in children and young adults with Marfan's syndrome.

Atenolol versus losartan in children and young adults with Marfan's syndrome. BACKGROUND: Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. METHODS: We conducted a randomized trial comparing losartan with atenolol in children and young adults with Marfan's syndrome. The primary outcome was the rate (...) centers enrolled 608 participants, 6 months to 25 years of age (mean [±SD] age, 11.5±6.5 years in the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-root z score greater than 3.0. The baseline-adjusted rate of change in the mean (±SE) aortic-root z score did not differ significantly between the atenolol group and the losartan group (-0.139±0.013 and -0.107±0.013 standard-deviation units per year, respectively; P=0.08). Both slopes were significantly less than zero

NEJM2014 Full Text: Link to full Text with Trip Pro

5. Losartan and enalapril are comparable in reducing proteinuria in children

Losartan and enalapril are comparable in reducing proteinuria in children 22739977 2012 11 08 2013 02 01 2015 11 19 1523-1755 82 7 2012 Oct Kidney international Kidney Int. Losartan and enalapril are comparable in reducing proteinuria in children. 819-26 10.1038/ki.2012.210 Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers delay progression of chronic kidney disease and have antiproteinuric effects beyond their effects on blood pressure. They are routinely (...) used in adults; however, their efficacy and safety in children, in whom the causes of chronic kidney disease are significantly different relative to adults, is uncertain. Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria. In this study, 268 children were re-randomized to losartan or enalapril and followed until 100

EvidenceUpdates2013

6. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis

Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic (...) review, meta- and cost-utility analysis Grosso AM, Bodalia PN, MacAllister RJ, Hingorani AD, Moon JC, Scott MA CRD summary The review found that candesartan appeared to reduce blood pressure slightly more than losartan, but that the difference may not be clinically significant. There was no good evidence that candesartan was superior to losartan for treating heart failure. These conclusions require some caution in interpretation due to limitations in the review, which included incomplete adherence

DARE.2012

7. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching

Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Baker TM, Goh J, Johnston A, Falvey H, Brede Y, Brown RE Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of valsartan, compared with losartan, and the impact of switching patients from valsartan to generic losartan, to lower blood pressure and prevent cardiovascular disease. The authors concluded that valsartan appeared to be cost-effective, compared with switching to generic losartan. Overall the quality of the study was adequate

NHS Economic Evaluation Database.2012

8. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis

Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic (...) candesartan and generic losartan in the treatment of hypertension and heart failure. The authors concluded that branded candesartan was not cost-effective compared with generic losartan, for the treatment of hypertension, from the perspective of the UK NHS. The cost-effectiveness framework was conventional and the clinical analysis was very well conducted. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-utility analysis Study objective The objective was to compare

NHS Economic Evaluation Database.2011

9. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension

A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension Zheng Z, Shi H, Jia J, Li D, Lin S CRD summary The authors concluded that candesartan was superior to losartan in reducing blood pressure. Candesartan seemed to cause (...) fewer serious adverse events than losartan. The authors' conclusion regarding blood pressure seemed appropriate for the short-term effects in the selected population. The limitations of the evidence suggest the reliability of the conclusions regarding serious adverse events remains uncertain. Authors' objectives To compare the effect of candesartan with losartan on blood pressure reduction, response and control rates and common and serious adverse events in patients with primary hypertension

DARE.2011

10. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension

Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension Meredith PA, Murray LS, McInnes GT CRD summary This review found that candesartan was associated with significantly greater reductions in blood (...) pressure in patients with hypertension compared with losartan. The results of this review should be interpreted with some caution, and the reliability of the authors' conclusions is uncertain due to the absence of a formal quality assessment and possible biases in the review process. Authors' objectives To evaluate the comparative efficacy of candesartan and losartan in in patients with hypertension. Searching PubMed, EMBASE (from inception) and the Cochrane Library were searched to October 2008 for relevant

DARE.2010

11. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy 19153265 2009 02 03 2009 03 04 2016 11 25 1524-4539 119 4 2009 Feb 03 Circulation Circulation Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. 530-7 10.1161/CIRCULATIONAHA (...) .108.826214 Left ventricular (LV) hypertrophy, a marker of cardiac end-organ damage, is associated with an increased risk of cardiovascular morbidity and mortality. Inhibitors of the renin-angiotensin-aldosterone system may reduce LV mass to a greater extent than other antihypertensive agents. We compared the effect of aliskiren, the first orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combination on the reduction of LV mass in hypertensive patients. We

EvidenceUpdates2009

12. Renal and retinal effects of enalapril and losartan in type 1 diabetes.

Renal and retinal effects of enalapril and losartan in type 1 diabetes. 19571282 2009 07 02 2009 07 07 2016 12 15 1533-4406 361 1 2009 Jul 02 The New England journal of medicine N. Engl. J. Med. Renal and retinal effects of enalapril and losartan in type 1 diabetes. 40-51 10.1056/NEJMoa0808400 Nephropathy and retinopathy remain important complications of type 1 diabetes. It is unclear whether their progression is slowed by early administration of drugs that block the renin-angiotensin system (...) . We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years. The primary end point was a change in the fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens. The retinopathy end point was a progression on a retinopathy severity scale of two steps or more. Intention-to-treat analysis

NEJM2009 Full Text: Link to full Text with Trip Pro

13. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. 19922995 2009 11 30 2009 12 11 2015 06 16 1474-547X 374 9704 2009 Nov 28 Lancet (London, England) Lancet Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. 1840-8 10.1016/S0140-6736(09)61913-9 Angiotensin-receptor blockers (ARBs) are effective treatments (...) for patients with heart failure, but the relation between dose and clinical outcomes has not been explored. We compared the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure. This double-blind trial was undertaken in 255 sites in 30 countries. 3846 patients with heart failure of New York Heart Association class II-IV, left-ventricular ejection fraction 40% or less, and intolerance to angiotensin-converting-enzyme (ACE) inhibitors were randomly assigned

Lancet2009

14. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial 18617301 2008 08 26 2008 09 18 2013 11 21 1523-6838 52 3 2008 Sep American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. 464-74 10.1053/j.ajkd.2008.05.012 Pentoxifylline potently inhibits cell proliferation, inflammation (...) , and extracellular matrix accumulation. Human studies have proved its antiproteinuric effect in patients with glomerular diseases. Its benefit in addition to angiotensin receptor blockade in patients with chronic kidney disease is not clear. Randomized controlled study. 85 patients with estimated glomerular filtration rate (eGFR) of 10 to 60 mL/min/1.73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National

EvidenceUpdates2008

15. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan 18272844 2008 04 29 2008 05 22 2014 09 04 1533-3450 19 5 2008 May Journal of the American Society of Nephrology : JASN J. Am. Soc. Nephrol. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. 999-1007 10.1681/ASN.2007060693 There is large interindividual variability in the antiproteinuric response to blockade of the renin-angiotensin-aldosterone system (RAAS (...) alone. Losartan monotherapy reduced proteinuria by 30%, and the addition of a low-sodium diet led to a total reduction by 55% and the addition of HCT to 56%. The combined addition of HCT and a low-sodium diet reduced proteinuria by 70% from baseline (all P < 0.05). Reductions in mean arterial pressure showed a similar pattern (all P < 0.05). In addition, individuals who did not demonstrate an antiproteinuric response to losartan monotherapy did respond when a low-sodium diet or a diuretic was added

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

17. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension

Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension Xi G L, Cheng J W, Lu G C CRD summary This generally well-conducted review found that telmisartan provided (...) better control of blood pressure than losartan in hypertensive patients without an increased risk of associated adverse events. The review appeared to be generally well conducted, however, the possible presence of publication bias and some clinical heterogeneity should be borne in mind when interpreting the conclusions. Authors' objectives To evaluate the effectiveness of telmisartan compared with losartan in hypertension and investigate the risk of associated adverse events. Searching PubMed (1966

DARE.2008

18. Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Aliskiren combined with losartan in type 2 diabetes and nephropathy. 18525041 2008 06 05 2008 06 19 2013 11 21 1533-4406 358 23 2008 Jun 05 The New England journal of medicine N. Engl. J. Med. Aliskiren combined with losartan in type 2 diabetes and nephropathy. 2433-46 10.1056/NEJMoa0708379 Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding (...) treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy. We enrolled 599 patients in this multinational, randomized, double-blind study. After a 3-month, open-label, run-in period during which patients received 100 mg of losartan daily, patients were randomly assigned to receive 6 months of treatment with aliskiren (150 mg

NEJM2008

19. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Usher-Smith J (...) from losartan to candesartan (4 mg candesartan per 25 mg losartan) for the control of hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population This study comprised two study populations. One was patients with a repeat prescription for atorvastatin, while the other was patients with a repeat prescription for losartan. The authors reported a variety of exclusion criteria. Setting The setting was outpatient, primary care. The economic study

NHS Economic Evaluation Database.2007

20. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study Cost-effectiveness of losartan-based therapy in patients (...) with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study McInnes G, Burke T A, Carides G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology

NHS Economic Evaluation Database.2006